<?xml version='1.0' encoding='utf-8'?>
<document id="23204624"><sentence text="Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital." /><sentence text="Polypharmacy is common in drug prescriptions of chronic kidney disease patients" /><sentence text=" A study of the prescription patterns of drugs with potential interactions would be of interest to prevent drug related adverse events" /><sentence text=" A prospective observational study of six months (Dec 2009-May 2010) was carried out among the chronic kidney disease patients admitted to the nephrology ward of a South Indian tertiary care hospital" /><sentence text=" The pattern and rates of drug-drug interactions seen in the prescriptions of these patients was studied" /><sentence text=" Among the 205 prescriptions included, a total of 474 interactions were reported, making 2" /><sentence text="7 interactions per prescription with incidence rates of 76" /><sentence text="09%" /><sentence text=" Around 19" /><sentence text="62% of interactions were of major severity" /><sentence text=" Most common interactions were found between ascorbic acid and cyanocobalamine (12"><entity charOffset="45-58" id="DDI-PubMed.23204624.s11.e0" text="ascorbic acid" /><entity charOffset="63-78" id="DDI-PubMed.23204624.s11.e1" text="cyanocobalamine" /><pair ddi="false" e1="DDI-PubMed.23204624.s11.e0" e2="DDI-PubMed.23204624.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23204624.s11.e0" e2="DDI-PubMed.23204624.s11.e1" /></sentence><sentence text="45%), clonidine and metoprolol (3"><entity charOffset="6-15" id="DDI-PubMed.23204624.s12.e0" text="clonidine" /><entity charOffset="20-30" id="DDI-PubMed.23204624.s12.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.23204624.s12.e0" e2="DDI-PubMed.23204624.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23204624.s12.e0" e2="DDI-PubMed.23204624.s12.e1" /></sentence><sentence text="80%) respectively" /><sentence text=" Hypo or hypertension (31" /><sentence text="65%), decreased drug efficacy (29" /><sentence text="11%) and hypo or hyperglycemia (14" /><sentence text="14%), were the most commonly reported clinical outcomes of the drug interactions" /><sentence text=" Cardiovascular drugs (calcium channel blockers and beta blockers; 52%) constitute the major class of drugs involved in interactions"><entity charOffset="23-30" id="DDI-PubMed.23204624.s18.e0" text="calcium" /></sentence><sentence text=" As most of the interactions had a delayed onset, long term follow-up is essential to predict the clinically significant outcomes of these interactions" /><sentence text=" Hence, drug interactions are commonly seen in the prescriptions of chronic kidney disease patients which can lead to serious adverse events if not detected early" /><sentence text=" Need for collaboration with a clinical pharmacist and electronic surveillance, which are absent in developing countries like India, is emphatic" /><sentence text="" /></document>